<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662220</url>
  </required_header>
  <id_info>
    <org_study_id>HCV07-01</org_study_id>
    <secondary_id>2007-005344-25</secondary_id>
    <nct_id>NCT00662220</nct_id>
  </id_info>
  <brief_title>High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4</brief_title>
  <acronym>VIRID</acronym>
  <official_title>High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimal ribavirin dosages are essential in achieving SVR (sustained virological response).
      Several studies have shown higher SVR rates in patients receiving higher doses of ribavirin.
      Therefore we propose a randomized controlled open label multicenter trial to investigate
      wether high (25-29mg/kg) dose ribavirin can improve outcome in patients in infected with
      hepatitis C virus genotype 1 or 4 compared to standard dose (12-15mg/kg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optimal ribavirin dosages are essential in achieving SVR. The initial evidence supporting
      higher doses of ribavirin for peginterferon alfa-2b comes from a secondary analysis of the
      pivotal multicenter trial of peginterferon alfa-2b and ribavirin. Patients receiving more
      than 10.6 mg/kg/day ribavirin experienced significantly higher SVR rates (48% vs. 38%). A
      large multicenter trial designed to test standard dose ribavirin (1000-1200 mg/day) versus
      low-dose ribavirin (800 mg/day) in combination with peginterferon alfa-2a, showed 52% SVR in
      the standard dose group versus 41% in the low-dose group for genotype 1 infected patients. In
      the pooled data from two pivotal studies with peginterferon alfa-2a and ribavirin, the
      probability of achieving an SVR for genotype 1 patients was influenced by the ribavirin dose
      per kg body weight. A 40-50% increase in the probability of SVR was found for a 12-16 mg/kg
      dose increase of ribavirin. For peginterferon alfa-2b it was also shown among genotype 1
      patients, that weight-based ribavirin (800-1400 mg/day) leads to higher SVR rates compared to
      fixed dose ribavirin (800 mg/day) (34% vs. 29%). Moreover, ribavirin dosing up to 1400 mg/day
      was safe and the rate of treatment discontinuation was the same for both treatment groups. In
      a small pilot study, 10 genotype 1 patients with a high baseline load were treated with
      peginterferon alfa-2a and individualized high-dose ribavirin in order to achieve a ribavirin
      target concentration in serum of 15 μmol/l. The mean ribavirin dose of 2540 mg/day (range
      1600-3600 mg/day) was high, but resulted in 90% SVR. All patients experienced severe anemia,
      which was treated with concomitant epoetin beta and blood transfusion.

      As mentioned before, the main concern of high-dose ribavirin will be a dose-dependent
      hemolytic anemia and the addition of epoetin alfa has shown significant increase of
      haemoglobin during (peg)interferon/ribavirin therapy. Erythropoietin doses from 9,000 to
      60,000 IU/week have been used in order keep the highest possible ribavirin doses. A recent
      trial showed a significant higher SVR rate in genotype 1 patients treated with peginterferon
      alfa-2b, increased dose ribavirin (15.2 mg/kg/day) and epoetin alfa than in patients treated
      with peginterferon alfa-2b and standard dose ribavirin (13.3 mg/kg/day) with or without
      epoetin alfa. Using the standard ribavirin dose, routine use of erythropoietin significantly
      decreased the frequency of anemia and the mean ribavirin dose reduction. Moreover, with the
      addition of erythropoietin, a significant higher mean dose could be given to patients in the
      increased ribavirin dose arm.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study
    had to be terminated.
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV-RNA negativity by qualitative assay 24 weeks after end of treatment (sustained virological response, SVR)</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV-RNA negativity at week 4 (rapid virological response, RVR)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV-RNA negativity at week 12 (complete early virological response, cEVR)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV-RNA ≥ 2log10 drop at week 12, but HCV-RNA still detectable (partial early virological response, pEVR)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV- RNA negativity at week 48 (end of treatment response, ETR)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate after ETR</measure>
    <time_frame>48 weeks - end of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of high-dose daily ribavirin (serious adverse events, grade 4 NCI toxicity, percentage of patients completing treatment on full or &gt;80% of total intended dose and reasons for dose adjustments)</measure>
    <time_frame>week 0 till end of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (normalization of serum ALT at the end of therapy and at the end of follow-up)</measure>
    <time_frame>week 0 - end of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life and psychopathology before, during and after treatment by SF-36 and SCL-90 questionnaires</measure>
    <time_frame>week 0 - week 72</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard-dose ribavirin (12-15 mg/kg/day) in combination with peginterferon 180µg QW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose ribavirin (25-29 mg/kg/day) in combination with peginterferon 180µg QW</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>25-29 mg/kg/day</description>
    <arm_group_label>High dose</arm_group_label>
    <other_name>Copegus</other_name>
    <other_name>Pegasys</other_name>
    <other_name>NeoRecormon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>12-15 mg/kg/day</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Copegus</other_name>
    <other_name>Pegasys</other_name>
    <other_name>NeoRecormon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hepatitis C genotype 1 or 4

          -  high viral load (&gt;400000 IU/ml)

          -  indication for antiviral treatment or patient's desire for antiviral treatment

          -  hepatitis C treatment naive

          -  liver biopsy within 3 years of screening visit or when biopsy is contraindicated e.g
             in patients with clotting diseases or when a patient refuses to undergo a new biopsy
             in case the liver biopsy is older than 3 years, substitution by fibroscan is allowed.

          -  age 18-70 years

        Exclusion Criteria:

          -  serum bilirubin &gt;35 μmol/l

          -  albumin &lt;36 g/l

          -  prothrombin time &gt;4 sec prolonged

          -  platelets &lt;90x109/l

          -  decompensated cirrhosis (Child-Pugh Grade B or C)

          -  hepatic imaging (ultrasound, CT or MRI) with the evidence of hepatocellular carcinoma
             (hepatic imaging should be performed within 3 months prior to screening for cirrhotic
             patients and within 6 months prior to screening for non-cirrhotic patients)

          -  alcoholic liver disease (indicator: MCV&gt;100)

          -  obesity induced liver disease (indicators: steatosis proven by biopsy or ultrasound in
             association with a body mass index &gt;30)

          -  drug related liver disease (indicator: positive history of hepatic toxic drug intake
             with a causal relation)

          -  auto-immune hepatitis (indicators: IgG &gt;30g/l, anti smooth-muscle or antinuclear
             antibodies titer ³1:40)

          -  hemochromatosis (indicator: ferritin &gt;1000 μg/l)

          -  Wilson's disease (indicator: ceruloplasmin (&lt;0.2 g/l)

          -  alpha-1 antitrypsin deficiency (indicator alpha-1 antitrypsin &lt;0.8 g/L)

          -  co-infection with hepatitis B virus or human immunodeficiency virus (HIV)

          -  any cardiovascular dysfunction (e.g. cardiac decompensation, myocardial infarction,
             present or history of arrythmia)

          -  other medical illness that might interfere with this study: significant pulmonary or
             renal dysfunction, malignancy other than skin basocellular carcinoma in previous 5
             years, immunodeficiency syndromes (e.g.: steroid therapy, organ transplants other than
             cornea and hair transplant)

          -  contra-indications for peginterferon and/or ribavirin:

          -  severe psychiatric disorder, such as major psychoses, suicidal ideation, suicidal
             attempt and/or manifest depression. Severe depression would include the following: (a)
             subjects who have been hospitalized for depression, (b) subjects who have received
             electroconvulsive therapy for depression, or (c) subjects whose depression has
             resulted in a prolonged absence of work and/or significant disruption of daily
             functions. Subjects with a history of mild depression may be considered for entry into
             the protocol provided that a pretreatment assessment of the subject's mental status
             supports that the subject is clinically stable and that there is ongoing evaluation of
             the patient's mental status during the study

          -  visual symptoms related to retinal abnormalities

          -  pregnancy, breast-feeding or inadequate contraception

          -  thalassemia, spherocytosis

          -  females who are pregnant or intending to become pregnant or male partners of females
             who are pregnant or intending to become pregnant

          -  absolute neutrophil count (ANC) &lt;1.40x109/l

          -  hemoglobin (Hb) &lt;7.5 mmol/l (female) or &lt;8.1 mmol/l (male)

          -  serum creatinine concentration &gt;1.5 times the upper limit of normal at screening

          -  substance abuse, such as I.V. drugs or alcohol (indicator: &gt;28 drinks/week). If the
             subject has a history of substance abuse, to be considered for inclusion into the
             protocol, the subject must have abstained from using the abused substance for at least
             1 year

          -  any other condition which in the opinion of the investigator would make the patient
             unsuitable for enrollment, or could interfere with the patient participating in and
             completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R J de Knegt, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J PH Drenth, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Radboud Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lucas hospital</name>
      <address>
        <city>Winschoten</city>
        <state>Groningen</state>
        <zip>9670RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <zip>6401CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia hospital</name>
      <address>
        <city>Breda</city>
        <state>Noord Brabant</state>
        <zip>4818CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord Brabant</state>
        <zip>5602ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twee Steden hospital</name>
      <address>
        <city>Tilburg</city>
        <state>Noord Brabant</state>
        <zip>5000LA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth hospital</name>
      <address>
        <city>Tilburg</city>
        <state>Noord Brabant</state>
        <zip>5000LC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord Holland</state>
        <zip>1815JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart hospital</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1006BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwen Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1090HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <state>Noord Holland</state>
        <zip>2130 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer hospital</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <zip>7415CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZorgSaam Hospital</name>
      <address>
        <city>Terneuzen</city>
        <state>Zeeland</state>
        <zip>4535PA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walcheren hospital</name>
      <address>
        <city>Vlissingen</city>
        <state>Zeeland</state>
        <zip>3200</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IJsselland hospital</name>
      <address>
        <city>Capelle aan de IJssel</city>
        <state>Zuid Holland</state>
        <zip>2906ZC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <state>Zuid Holland</state>
        <zip>2600GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HAGA Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid Holland</state>
        <zip>2545CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer hospital</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid Holland</state>
        <zip>3300AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Franciscus hospital</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3004BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad hospital</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3078HT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groningen University Medical Center</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>ribavirin</keyword>
  <keyword>SVR</keyword>
  <keyword>genotype one</keyword>
  <keyword>genotype four</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

